GlassScriptPhysician profile
Zarmine Naccashian
$3,165.86
in general payments reported to CMS, 2019-2025
13 companies · $551 in 2025
The $551 reported for 2025 was more than what 80% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $125 · 2022: $806 · 2023: $742 · 2024: $942 · 2025: $551.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,008 · Education: $227.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,007.89 |
| Education | $226.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,013.37 | 2022-2025 | Ozempic, Wegovy |
| Edwards Lifesciences Corporation | $673.86 | 2022-2024 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Regeneron Healthcare Solutions, INC. | $372.42 | 2022-2024 | Dupixent |
| Abbvie INC. | $279.17 | 2023-2025 | |
| Boston Scientific Corporation | $182.17 | 2021-2022 | |
| Grt US Holding, INC. | $142.52 | 2022 | |
| Amgen INC. | $125.04 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $99.22 | 2024 | Austedo Xr |
| Biogen, INC. | $95.19 | 2023 | |
| Otsuka America Pharmaceutical, INC. | $79.50 | 2025 | Rexulti |
| Astrazeneca Pharmaceuticals LP | $61.96 | 2024 | |
| Novartis Pharmaceuticals Corporation | $23.27 | 2023 | |
| Gilead Sciences, INC. | $18.17 | 2023 | Veklury |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zarmine Naccashian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.